Solid Biosciences’ (SLDB) Buy Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Solid Biosciences (NASDAQ:SLDB) in a research report released on Friday morning,Benzinga reports. The firm currently has a $16.00 price objective on the stock.

A number of other research analysts also recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Solid Biosciences in a report on Friday, January 10th. JPMorgan Chase & Co. lowered their target price on Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Wedbush started coverage on Solid Biosciences in a research report on Friday, December 13th. They set an “outperform” rating and a $16.00 price target on the stock. Citizens Jmp raised Solid Biosciences to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, JMP Securities began coverage on Solid Biosciences in a research note on Tuesday, December 10th. They set an “outperform” rating and a $15.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, Solid Biosciences currently has a consensus rating of “Buy” and an average target price of $15.40.

Solid Biosciences Trading Down 1.5 %

Solid Biosciences stock opened at $5.42 on Friday. The firm has a market capitalization of $413.65 million, a P/E ratio of -1.78 and a beta of 1.98. The stock has a fifty day moving average price of $4.07 and a 200 day moving average price of $5.56. Solid Biosciences has a 52 week low of $2.88 and a 52 week high of $15.05.

Institutional Trading of Solid Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Solid Biosciences during the 4th quarter worth about $34,000. Corton Capital Inc. bought a new stake in shares of Solid Biosciences in the 4th quarter valued at approximately $41,000. Invesco Ltd. bought a new stake in shares of Solid Biosciences in the 4th quarter valued at approximately $49,000. Sei Investments Co. bought a new stake in Solid Biosciences during the 4th quarter worth approximately $52,000. Finally, Wells Fargo & Company MN grew its position in Solid Biosciences by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 13,138 shares of the company’s stock worth $53,000 after acquiring an additional 2,986 shares during the last quarter. Institutional investors and hedge funds own 81.46% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.